INTRODUCTION
Neuroendocrine tumours (NET) develop from the di use neuroendocrine system and are most often located in the gastrointestinal tract, including the pancreas (60-70%) and in the lungs (25-30%) [1] . e tumours are rare but are increasing in incidence according to the North American Surveillance, Epidemiology and End Results Programme [1, 2] . e NET is a highly heterogeneous disease with di erent organ locations, staging and grading. As a consequence of the heterogeneous nature of NET, treatment of the disease varies from surgery to di erent pharmacological treatments and radionuclide therapy [3] .
Neuroendocrine tumors' diagnosis and disease status evaluation during follow-up are based on clinical symptoms, imaging methods and circulating tumour markers. In particular, the tumour marker chromogranin A (CgA) has been shown to be a universal marker for NET, and CgA is currently the single most important tumour marker used in the diagnosis and follow-up of NET patients [4] . Chromogranin A levels are elevated in variable degrees in most patients with NET [5, 6] .
Chromogranin A is an acidic glycoprotein consisting of 439 amino acids with a molecular mass of 48 kDa. It is stored in the dense secretory granules of the cytoplasm of neuroendocrine and endocrine cells and is co-secreted upon stimulation of these cells together with peptide hormones and neuropeptides [7] . Chromogranin A from both non-pathological and J Gastrointestin Liver Dis, December 2014 Vol. 23 No 4: 419-424 pathological neuroendocrine cells is post-translationally processed into di erent fragments. is post-translational processing may be di erent in di erent tissues and also in di erent tumours, and this may have an impact on the CgA assessment by di erent assays [8] .
For both diagnosis and follow-up of NET patients it is important to have a CgA assay with high sensitivity and speci city. At diagnosis, elevated levels of CgA will result in further diagnostic investigations to establish the NET diagnosis and staging, which is required for initiation of speci c NET treatment. During follow-up, increases in CgA levels raise suspicion of NET recurrence or disease progression with the need for further investigations and a possible change in treatment modality [9] . Opposite, false positive CgA levels may lead to a number of unnecessary investigations with increased costs for the individual patient and the health care system.
Chromogranin A levels can be elevated for other reasons than the presence of NET disease. e most common causes are proton pump inhibitor (PPI) treatment, chronic atrophic gastritis and renal insu ciency. Other well known causes include in ammatory bowel disease and liver failure [10] .
e aim of the present study was to compare the clinical sensitivity of three different CgA assays in patients with known NET using the cut-o values recommended by the manufacturers of the respective assays. e assays compared were an in-house RIA assay, RH RIA assay (Rigshospitalet, Copenhagen, Denmark) and two commercial assays: NEOLISA TM (Euro Diagnostica, Malmö, Sweden) and EURIA CgA RIA (Euro Diagnostica, Malmö, Sweden). e in-house assay is used for CgA measurements at ENETS Centres of Excellence in Denmark, while the EURIA CgA RIA assays are used at several NET centres in Europe.
METHODS

Patients
A total of 42 patients histologically diagnosed with NET were included from the Department of Medicine V (Hepatology and Gastroenterology), Aarhus University Hospital, Denmark, in the period December 2010 to April 2011. Disease status was evaluated using computed tomography (CT, n = 38), magnetic resonance imaging (MRI, n = 7), somatostatin receptor imaging by computed tomography (CT) in combination with positron emission tomography (Ga-Dotanoc PET-CT, n = 11) and/or single photon emission computed tomography (SPECT-CT, n = 18). e latter two scans were combined with diagnostic CT scans, all performed as 3-phase CT scans with i.v. contrast enhancement. Follow-up with CT-scans on radically resected NET patients was performed up to 12 months a er inclusion in the study. e study was approved by the local Ethics Committee, Region Midtjylland (133/2012).
Assays
The RH RIA assay is an in-house assay developed at Rigshospitalet (Copenhagen, Denmark) in 1999 from a library of RIAs speci c for di erent epitopes, including the NH 2 and COOH termini and three sequences adjacent to dibasic sites in the remaining part of CgA [10] . e polyclonal antibodies in the present RIA are raised in rabbits and bind di erent epitopes between amino acid residue 340 of the CgA molecule and amino acid residues in the C-terminal direction, including e.g. amino acid residue 340-348 of the CgA molecule [10] .
e CgA measurement has been improved in 2007 by treating samples with trypsin in a processing-independent analysis (PIA) followed by measurement of CgA by the RIA [11] . For determination of cut-o (set to <130 pmol/L), 88 healthy controls, 50% males and 50% females, median age for all 41 years (IQR 30-51) and 27 patients with gastrointestinal NET, 44% women, median age for all 60 years (IQR 57-70) were studied were studied [11, 12] .
e NEOLISA is an enzyme-linked immunosorbent assay (ELISA) using two monoclonal antibodies raised in mice. e catching antibodies bind an epitope starting at amino acid residue 236 and ending at amino acid residue 251. e detector antibodies bind an epitope from amino acid residue 264 to 279. e cut-o value for the NEOLISA was <3 nmol/L de ned by the manufacturer.
e EURIA assay is a competitive RIA using polyclonal antibodies raised in rabbits directed towards epitopes between amino acid residue 116 to aminoacid residue 439 in the CgA peptide. The cut-off value for the EURIA defined by the manufacturer was <6 nmol/L.
Plasma samples
For plasma collection we used K2-EDTA tubes (Terumo, Herlev, Denmark). Samples were kept on ice and centrifuged for nine minutes (1850 g, 4 0 C) within one hour a er blood collection. A er centrifugation samples were immediately frozen and stored at -20 0 C until analysis. Analysis and calibration were carried out according to the recommendations of the manufacturers.
Statistical analysis
Sensitivities were calculated using SPSS (version 18.0). Comparisons of the individual assays between groups were performed by the non-parametric Kruskall-Wallis test followed by the Mann-Whitney test. Correlations between assays were performed by Spearmans rho. Bland Altman plots and Box plots are provided for the three assays (Figs. 1, 2) .
RESULTS
Patients᾿ characteristics
e 42 patients included in the study were 23 males and 19 females, with a median age of 63 years (range 29-85 years).
irty-three patients had clinically manifest NET disease at the time of blood sampling veri ed by imaging techniques. Of these, 25 patients had liver metastases and 8 had regional disease classi ed as the presence of the primary tumour and/ or metastases to other sites than the liver. e remaining 9 patients were radically operated with removal of their primary tumour and no evidence of metastatic disease. Table I shows the primary tumour locations for the 33 patients with present NET disease and the 9 radically operated patients.
Among the 25 NET patients with liver metastases, 20 patients (9 with pancreatic NET, 7 with small bowel NET, 1 with lung NET, 1 with cecal NET and 2 with unknown primary NET) had elevated CgA levels measured by all three assays, and 1 patient (small bowel NET) had a normal CgA level measured by all three assays. e remaining 4 patients (3 small bowel NET and 1 unknown primary NET) had elevated levels of CgA using the RH RIA assay while normal CgA levels using the NEOLISA and EURIA assays.
In the 8 NET patients with regional disease, 6 patients (3 pancreatic NET, 1 small bowel NET, one appendix goblet NET and 1 unknown primary NET) had elevated CgA levels measured by all three assays. Two patients (lung NET) had elevated CgA levels measured by the RH RIA assay while normal CgA levels measured by the NEOLISA and EURIA assays.
In the 9 patients free from NET a er surgery, 3 (2 small bowel NET, 1 lung NET) had elevated CgA levels measured by all assays, while 2 patients (1 rectal NET, 1 lung NET) had normal CgA levels measured by all assays. e remaining 4 NET patients (1 for each of the following locations: small bowel, lung, rectal and pancreatic) had elevated CgA levels in plasma using the RH RIA assay, but normal levels using the NEOLISA and EURIA assay.
Assay sensitivity and comparison
We evaluated the clinical sensitivity of the RH RIA, NEOLISA and EURIA assays in patients with known NET using the cut-o values recommended by the manufacturers. Table II illustrates that the RH RIA assay showed plasma CgA levels elevated in 32 and normal in 1 of the patients with present NET disease. e clinical sensitivity of the RH RIA assay was 97%. In the 9 patients free from tumour a er radical surgery, CgA levels were elevated in 7 and normal in 2.
Using the NEOLISA and EURIA assays, we found that plasma CgA levels were similarly elevated in 26 of the 33 patients with present NET and normal in the remaining 7 patients. In the 9 patients without present NET, CgA levels were elevated in 3 and normal in 6. Accordingly, the clinical sensitivity of the NEOLISA and EURIA assays was of 79%.
A strong correlation was found between CgA measurements by the NEOLISA and EURIA assays (r= 0.97, P<0.0001), while the correlation with the RH RIA assay was slightly weaker (r= 0.86 for NEOLISA, and r= 0.80 for EURIA; for both P<0.000). For the NEOLISA and EURIA assays there were no di erences regarding which patients had normal and elevated levels of CgA mesured when compared according to the assay cut-o values. However, when comparing the RH RIA assay with the NEOLISA/EURIA assays we found incongruencies among patients who were considered as having normal or elevated CgA levels (Table III) . Using Bland Altman plots we showed that the RH RIA assay performed di erently compared to the NEOLISA and EURIA, which showed more comparable values (Fig. 1) . Values above 50 nmol/L for the NEOLISA and EURIA assay are not included in the Bland Altman plots as they were de ned as values > 50 nmol/L (7 patient samples).
ere was a signi cant di erence in CgA levels dependent of disease stage (Fig. 2) , with a signi cant di erence between patients with liver metastases compared to disease free patients for all three assays (P<0.001). ere was no di erence in CgA levels between disease free patients and patients with regional disease. Only the RH RIA assay demonstrated a signi cant di erence between patients with regional disease and liver metastases (P<0.01).
During follow-up of radically resected NET patients, one patient with lung NET developed radiologically con rmed recurrence at three months a er blood sampling. is patient had elevated CgA levels measured by all three assays. For one patient no scans were performed in the follow-up period. For the remaining seven patients, the scans performed during the 12 month follow-up revealed no signs of recurrence.
Kidney function and proton pump inhibitor treatment
Eight of the 42 patients had renal insu ciency de ned as elevated plasma creatinine (reference intervals: 60-105 μmol/L for men and 45-90 μmol/L for women) and diminished glomerular ltration rate (GFR) (reference interval > 60 mL/ min). Five patients with liver metastases and two with regional disease had elevated levels of CgA. e last patient (83 years old female with hypertension) was free from NET a er radical surgery; she had elevated levels of CgA by all three assays, a creatinine level of 152 μmol/L and GFR 28 ml/min. elevated CgA levels by RH RIA assay; seven had elevated CgA levels also by the NEOLISA and EURIA assays.
Two of the 42 patients had been diagnosed with ulcerative colitis, and both were radically operated for their NET without residual disease at the time of blood sampling. ey were treated with Mesalazin (5-ASA). In both cases, CgA levels were elevated using the RH RIA assay but normal using the NEOLISA and EURIA assays.
DISCUSSION
Chromogranin A is the most important general tumour marker used in the diagnosis and follow-up of patients with NET. e main nding in the present study was the marked di erence in the clinical sensitivity of the three assays. e in-house RIA assay from Rigshospitalet, Copenhagen had a higher clinical sensitivity than the two commercially available assays from Euro Diagnostica.
We con rmed that the increase in CgA levels to some extent depends on tumour status [13, 14] ; however, the present study also demonstrated a signi cant di erence between patients with regional disease and patients with liver metastases when using the RH RIA assay. is may suggest that the RH RIA assay better predicts disease status compared to the commercially available assays investigated.
Our nding that the clinical sensitivities of CgA assays di er is in line with ndings from other studies. Stridsberg et al compared three di erent commercial CgA assays [CGA-RIA CT (CIS bio international, Gif-Sur-Yvette, Cedex, France); DAKO Chromogranin A ELISA kit (DAKO A/S, Glostrup, Denmark) and CgA (Euro Diagnostica, Malmö, Sweden)] with sensitivities of 67%, 85% and 93%, respectively [8] . Zatelli et al compared the CGA-RIA CT from CIS bio international and the DAKO Chromogranin A ELISA assay from DAKO A/S and found sensitivities of 78% and 84%, respectively [14] . Ferrari et al also compared the CGA-RIA CT from CIS Bio international and the DAKO Chromogranin A ELISA assay from DAKO A/S and found a sensitivity of 79% for both assays [15] . Comparison of the sensitivities found in these studies is, however, di cult as di erent cut-o values are used in the studies. For the CGA-RIA CT assay the cut-o value was < 99 ng/mL in the study by Stridsberg et al, <70 ng/mL in the study by Ferrari et al and < 53 ng/mL in the study by Zatelli et al. Similarly, the cut-o values used in the evaluation of the DAKO Chromogranin A ELISA assay e cut-o value for an assay is important for the sensitivity of the assay and we investigated whether the cut-o value could explain the di erent sensitivities of the assays evaluated. In cases with present NET and elevated CgA by the RH RIA assay but normal CgA levels by the NEOLISA assay, we found that the CgA values measured by NEOLISA were relatively far from the cut-o value of < 3 nmol/L recommended by the manufacturer. is means that it is not desirable to change the cut-o value of this assay in order to reach a higher sensitivity. Similarly, for the EURIA assay, the normal CgA levels measured in patients with present NET disease and elevated CgA levels using the RH RIA assay were relatively far from the cut-o value of < 6 nmol/L recommended by Eurodiagnostica.
Comparison between studies is also difficult due to differences in the study populations. Campana et al demonstrated lower CgA levels in patients with lung NET compared to patients with gastroenteropancreatic NET [16] .
erefore, studies comprising a relatively large number of lung NET patients could be assumed to nd lower sensitivities of CgA assays compared to studies with a higher proportion of gastroenteropancreatic NET patients. This should be considered in the interpretation of the studies evaluating CgA as a tumour marker.
We followed patients free from NET after surgery to investigate if they later developed recurrence. One patient with pulmonary NET had recurrence. e remaining seven patients followed-up for 12 months had no signs of recurrence. We investigated if the elevated CgA levels observed in patients free from NET a er surgery could be explained by other causes. In three patients, co-morbidity might have contributed to the elevated CgA levels: renal insu ciency (1) or ulcerative colitis (2) . None of the patients received PPIs, and none had chronic atrophic gastritis or liver failure.
e present study has some strengths and limitations. We investigated the clinical sensitivity of the three CgA assays in 42 patients with NET, all well characterised by relevant imaging methods and pathology reports. We did not include healthy controls and are therefore not able to draw conclusions regarding the ability of the assays to di erentiate between patients with NET and healthy individuals. Future studies should include a larger number of NET patients and also a group of age and gender matched controls.
CONCLUSION
e clinical sensitivity of CgA measurements is assay dependent. The in-house RH RIA assay was better at predicting NET status than the two commercial NEOLISA and EURIA assays. us, caution should be applied in the interpretation of CgA measurements for the assessment of NET status.
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